北京时间11月5日凌晨消息，美国司法部周一宣布，强生(93.03, -0.34, -0.36%)公司(JNJ)已同意支付22亿美元，以了结有关其向医生和药房提供回扣，以及非法营销药物用于未经批准用途的刑事和民事调查。

此次和解牵涉到强生及其子公司杨森制药，涉及的药物包括精神分裂症治疗药物Risperd，抗精神病药物Invega，以及心脏病药物Natrecor。

在总计22亿美元的罚款当中，有17.2亿美元是支付给美国联邦和州政府的民事和解金，另有4.85亿美元是刑事罚款和没收利润。

Risperdal是由杨森制药负责销售的，据消息人士称，杨森预计将承认错误标签的轻罪指控。

CNN的报道

Health care manufacturer Johnson & Johnson and its subsidiaries will pay more than $2.2 billion to resolve criminal and civil investigations over allegations that they marketed three drugs for uses that were never approved, U.S. Attorney General Eric Holder said Monday in Washington.

The settlements also cover claims that the companies gave "kickbacks" to physicians and to nursing home pharmacies to promote the drugs' usage.

The claims involve the schizophrenia drugs Risperdal and Invega and the heart-failure drug Natrecor.

Holder said Johnson & Johnson improperly marketed Risperdal for treatment of psychotic symptoms in elderly, non-schizophrenic patients, even though the drug was approved to treat only schizophrenia.

He said Risperdal and Invega also were improperly marketed for dementia treatment.

That led insurance companies to pay for claims they never should have been paying, he said.

The companies "lined their pockets at the expense of American taxpayers (and) patients," Holder said.

Natrecor was marketed as a treatment for patients with less severe heart failure than mentioned in its Food and Drug Administration approval, according to the Department of Justice.